

CYTOKINETICS INC  
Form 8-K  
November 23, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 17, 2016**

**Cytokinetics, Incorporated**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**000-50633**  
**(Commission**  
  
**File Number)**

**94-3291317**  
**(I.R.S. Employer**  
  
**Identification No.)**

**94080**

**280 East Grand Avenue, South San  
Francisco, California**

**(Address of principal executive  
offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (650) 624 - 3000**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 17, 2016, Sharon A. Barbari, Executive Vice President of Finance and Chief Financial Officer of Cytokinetics, Incorporated, provided notice that she intends to retire in the second quarter of 2017. Ms. Barbari anticipates participating in the identification of her successor and assisting in a smooth transition of her responsibilities.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CYTOKINETICS, INCORPORATED**

Dated: November 23, 2016

By: /s/ Sharon A. Barbari  
Sharon A. Barbari

Executive Vice President and Chief Financial  
Officer